TIL
Instil Bio, Inc. NASDAQ Listed Mar 19, 2021$8.03
Mkt Cap $54.5M
52w Low $5.67
6.4% of range
52w High $42.79
50d MA $8.40
200d MA $14.60
P/E (TTM)
-0.7x
EV/EBITDA
-2.9x
P/B
0.5x
Debt/Equity
0.8x
ROE
-62.7%
P/FCF
-2.0x
RSI (14)
—
ATR (14)
—
Beta
2.03
50d MA
$8.40
200d MA
$14.60
Avg Volume
40.7K
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
3963 Maple Avenue · Dallas, TX 75219 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -2.31 | -1.21 | +47.6% | 7.79 | +0.8% | +2.3% | +3.4% | -2.5% | +0.0% | +5.4% | — |
| Nov 13, 2025 | AMC | -2.00 | -2.01 | -0.5% | 13.91 | -2.9% | +3.7% | -11.4% | +1.8% | -6.2% | -1.9% | — |
| Aug 13, 2025 | AMC | -1.72 | -3.24 | -88.4% | 26.97 | -4.0% | +4.7% | -1.5% | +3.7% | -11.6% | -0.7% | — |
| May 13, 2025 | AMC | -2.02 | -4.32 | -113.9% | 12.74 | +0.8% | +4.3% | +11.4% | -1.2% | +15.5% | -2.7% | — |
| Mar 4, 2025 | AMC | -3.75 | -1.82 | +51.5% | 17.50 | +0.9% | +3.1% | +6.3% | -4.6% | -9.9% | +5.2% | — |
| Nov 13, 2024 | AMC | -2.08 | -3.54 | -70.2% | 31.54 | +4.6% | -6.7% | -10.0% | -6.2% | +5.3% | -10.8% | — |
| Aug 13, 2024 | AMC | -3.04 | -2.29 | +24.7% | 10.35 | +8.2% | +1.1% | -2.3% | -1.6% | +9.2% | +5.7% | — |
| May 10, 2024 | AMC | -2.16 | -3.74 | -73.1% | 11.58 | +1.6% | +1.9% | +0.7% | +1.9% | -2.5% | -2.5% | — |
| Mar 21, 2024 | AMC | -2.84 | -1.99 | +29.9% | 11.77 | -0.2% | -1.5% | -3.7% | -1.3% | +0.8% | -2.7% | — |
| Nov 13, 2023 | AMC | -2.80 | -10.40 | -271.4% | 7.20 | -2.8% | -5.4% | -0.7% | -0.5% | +7.1% | +5.3% | — |
| Aug 14, 2023 | AMC | -4.00 | -2.20 | +45.0% | 9.88 | -2.2% | +2.4% | -3.2% | -1.9% | -2.0% | +1.7% | — |
| Mar 31, 2023 | AMC | -9.00 | -7.20 | +20.0% | 13.22 | +0.0% | -0.1% | -3.3% | +3.4% | +0.9% | -1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 7 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $6.66 | $6.69 | +0.5% | +7.8% | +2.9% | -3.5% | +0.3% | +0.7% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.98 | $23.94 | +4.2% | +3.6% | +1.3% | +7.0% | -10.6% | -6.5% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.41 | $28.02 | -1.4% | -1.4% | -1.3% | -2.3% | +8.2% | -0.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.25 | $28.65 | +1.4% | -1.5% | +3.7% | -11.6% | -0.7% | +4.7% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.40 | $33.95 | -1.3% | -11.8% | +8.4% | +6.6% | +7.1% | -2.7% |
| Jun 2 | JMP Securities | Maintains | Market Perform → Market Perform | — | $26.95 | $35.14 | +30.4% | +10.0% | +0.8% | +15.1% | -11.8% | +8.4% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.61 | $23.90 | -2.9% | -14.6% | +15.2% | +10.5% | +13.5% | -11.2% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.22 | $18.40 | +13.4% | +51.7% | -14.6% | +15.2% | +10.5% | +13.5% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.50 | $17.66 | +0.9% | +3.1% | +6.3% | -4.6% | -9.9% | +5.2% |
| Feb 13 | JMP Securities | Maintains | Market Perform → Market Perform | — | $19.17 | $19.43 | +1.4% | +24.4% | -3.5% | +8.6% | +2.9% | -6.6% |
| Jan 7 | Jefferies | Upgrade | Hold → Buy | — | $20.35 | $22.39 | +10.0% | +14.8% | -5.9% | -9.8% | -4.2% | +5.3% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.50 | $26.50 | +0.0% | -6.2% | +5.3% | -10.8% | +6.0% | +5.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.54 | $33.00 | +4.6% | -6.7% | -10.0% | -6.2% | +5.3% | -10.8% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.31 | $58.02 | -9.8% | +0.7% | +2.0% | -11.1% | +12.8% | +1.9% |
| Sep 16 | Baird | Maintains | Outperform → Outperform | — | $84.52 | $73.00 | -13.6% | -23.9% | +0.7% | +2.0% | -11.1% | +12.8% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $84.52 | $73.00 | -13.6% | -23.9% | +0.7% | +2.0% | -11.1% | +12.8% |
| Sep 13 | Baird | Maintains | Outperform → Outperform | — | $46.46 | $50.00 | +7.6% | +81.9% | -23.9% | +0.7% | +2.0% | -11.1% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.65 | $29.70 | +0.2% | +56.7% | +81.9% | -23.9% | +0.7% | +2.0% |
| Aug 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.50 | $12.40 | -0.8% | +8.4% | -2.4% | -2.7% | -1.7% | -0.8% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.84 | $11.36 | -4.1% | -4.4% | +0.7% | -4.5% | +7.5% | -7.8% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $11.77 | +1.6% | +1.9% | +0.7% | +1.9% | -2.5% | -2.5% |
| May 13 | Baird | Maintains | Outperform → Outperform | — | $11.58 | $11.77 | +1.6% | +1.9% | +0.7% | +1.9% | -2.5% | -2.5% |
| Apr 12 | Jefferies | Downgrade | Buy → Hold | — | $11.06 | $10.96 | -0.9% | -1.4% | -4.2% | -1.1% | +2.5% | -1.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.59 | $11.50 | -0.8% | -3.7% | -1.3% | +0.8% | -2.7% | -2.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.57 | $9.69 | +1.3% | +14.2% | -2.3% | +11.7% | -1.9% | +2.1% |
| Jan 19 | Baird | Maintains | Outperform → Outperform | — | $9.60 | $9.60 | +0.0% | -0.3% | +14.2% | -2.3% | +11.7% | -1.9% |
| Jan 17 | Baird | Maintains | Outperform → Outperform | — | $7.44 | $7.65 | +2.8% | +21.2% | +6.4% | -0.3% | +14.2% | -2.3% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.20 | $7.00 | -2.8% | -5.4% | -0.7% | -0.5% | +7.1% | +5.3% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.12 | $10.16 | +0.4% | -3.2% | -1.9% | -2.0% | +1.7% | -5.4% |
| Dec 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | — | — | — | — | — | — | — | — |
| Nov 16 | Baird | Maintains | Outperform → Outperform | — | $42.20 | $42.60 | +0.9% | -6.6% | -8.6% | -7.2% | -4.8% | -1.3% |
| Oct 31 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $105.00 | $68.60 | -34.7% | -37.1% | -20.3% | +0.8% | -1.5% | -3.1% |
| Oct 31 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $105.00 | $68.60 | -34.7% | -37.1% | -20.3% | +0.8% | -1.5% | -3.1% |
| Oct 31 | Baird | Maintains | Outperform → Outperform | — | $105.00 | $68.60 | -34.7% | -37.1% | -20.3% | +0.8% | -1.5% | -3.1% |
| Sep 5 | Baird | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 23 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $104.80 | $104.60 | -0.2% | +1.5% | +6.2% | -0.2% | -9.2% | -1.2% |
| Aug 22 | Truist | Maintains | Buy → Buy | — | $114.00 | $111.40 | -2.3% | -8.1% | +1.5% | +6.2% | -0.2% | -9.2% |
| Jun 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | — | — | — | — | — | — | — | — |
| May 23 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $145.40 | $146.40 | +0.7% | +7.6% | +3.5% | +4.5% | -6.2% | -24.3% |
| Aug 13 | Baird | Maintains | Outperform → Outperform | — | $329.00 | $344.00 | +4.6% | +0.5% | -1.7% | -0.4% | -0.8% | -0.4% |
| May 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $360.60 | $359.00 | -0.4% | -5.7% | +0.9% | +3.2% | +0.6% | -3.4% |
| Apr 13 | Jefferies | Maintains | Buy → Buy | — | $438.80 | $409.20 | -6.7% | -4.9% | -4.1% | -6.6% | +1.7% | -2.7% |
| Apr 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $438.80 | $409.20 | -6.7% | -4.9% | -4.1% | -6.6% | +1.7% | -2.7% |
| Apr 13 | Cowen & Co. | Maintains | Outperform → Outperform | — | $438.80 | $409.20 | -6.7% | -4.9% | -4.1% | -6.6% | +1.7% | -2.7% |
| Apr 13 | Truist | Maintains | Buy → Buy | — | $438.80 | $409.20 | -6.7% | -4.9% | -4.1% | -6.6% | +1.7% | -2.7% |
No insider trades available.
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
Instil Bio's auditor resignation raises red flags about potential accounting disputes or financial irregularities, warranting investor scrutiny of disclosed issues before the stock's next report.
Apr 3
8-K
Unknown — 8-K Filing
Instil Bio's $76.3M cash runway extending beyond 2027 reduces near-term dilution risk, but active M&A evaluation suggests management may pursue transformative deals that could substantially alter shareholder value and risk profile.
Mar 27
Data updated apr 27, 2026 4:47am
· Source: massive.com